Next Article in Journal
Influenza Vaccination Rates Among Parents and Health Care Personnel in a German Neonatology Department
Next Article in Special Issue
Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B
Previous Article in Journal
Structural Analysis and Epitope Prediction of MHC Class-1-Chain Related Protein-A for Cancer Vaccine Development
Previous Article in Special Issue
TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis
Article Menu

Export Article

Open AccessArticle
Vaccines 2018, 6(1), 2;

Structural and Immunological Characterization of Novel Recombinant MOMP-Based Chlamydial Antigens

National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02118, USA
Department of Physiology & Biophysics and the Amyloidosis Treatment and Research Center, Boston University School of Medicine, Boston, MA 02118, USA
SutroVax, Inc., Foster City, CA 94404, USA
Department of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA
Author to whom correspondence should be addressed.
Received: 30 October 2017 / Revised: 2 December 2017 / Accepted: 21 December 2017 / Published: 25 December 2017
(This article belongs to the Special Issue TLR signaling in Immune Response)
Full-Text   |   PDF [3987 KB, uploaded 25 December 2017]   |  


Chlamydia is the most common cause of bacterial sexually transmitted infections worldwide. While infections resolve with antibiotic treatment, this is often neglected in women due to frequent asymptomatic infections, leading to disease progression and severe sequelae (pelvic inflammatory disease, ectopic pregnancy, infertility). Development of a vaccine against Chlamydia is crucial. Whole organism-based vaccines have short-lived activity, serovar/subgroup-specific immunity and can cause adverse reactions in vaccinated subjects. The Chlamydia major outer membrane protein (MOMP) is a prime candidate for a subunit vaccine. MOMP contains four regions of sequence variability (variable domains, VDs) with B-cell and T-cell epitopes that elicit protective immunity. However, barriers for developing a MOMP-based vaccine include solubility, yield and refolding. We have engineered novel recombinant antigens in which the VDs are expressed into a carrier protein structurally similar to MOMP and suitable for recombinant expression at a high yield in a correctly folded and detergent-free form. Using a carrier such as the PorB porin from the human commensal organism N. lactamica, we show that PorB/VD chimeric proteins are immunogenic, antigenic and cross-reactive with MOMP. VDs are unique for each serovar but if combined in a single vaccine, a broad coverage against the major Chlamydia serovars can be ensured. View Full-Text
Keywords: vaccine; Chlamydia; MOMP; neisseria; PorB; porins; TLR2 vaccine; Chlamydia; MOMP; neisseria; PorB; porins; TLR2

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Madico, G.; Gursky, O.; Fairman, J.; Massari, P. Structural and Immunological Characterization of Novel Recombinant MOMP-Based Chlamydial Antigens. Vaccines 2018, 6, 2.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top